查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1841984

北美活性藥物成分市場規模、佔有率和趨勢分析報告：按合成類型、製造商、類型、應用、國家和細分市場預測，2025 年至 2033 年

North America Active Pharmaceutical Ingredients Market Size, Share & Trends Analysis Report By Type Of Synthesis, By Type Of Manufacturer, By Type, By Application, By Country, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

北美活性藥物成分市場摘要

北美活性藥物成分市場規模預計在 2024 年達到 9,664 萬美元，預計到 2033 年將達到 1.4734 億美元，2025 年至 2033 年的複合年成長率為 4.76%。

學名藥需求的不斷成長、生物技術的進步、人口老化以及有利的監管支持正在推動這一成長。

擁有強大製造能力的老牌製藥公司的存在進一步支持了市場擴張。北美 API 市場正在經歷重大變革時期，推動這項轉型的因素包括監管措施、技術進步和旨在加強國內製造能力的策略投資。該市場中最引人注目的新興市場發展之一是美國政府為確保更具彈性的醫藥供應鏈所做的努力。 2025 年 8 月，唐納德·川普總統簽署了一項行政命令，設立戰略活性藥物成分儲備庫 (SAPIR)，以儲存國家健康和安全所需的關鍵藥物成分。這項由美國衛生與公眾服務部支持的策略性舉措凸顯了全球 API 供應鏈日益成長的脆弱性，尤其是在 COVID-19 大流行造成中斷之後。此舉旨在減少對海外供應商的依賴，並確保在緊急情況和中斷期間隨時獲得基本藥物。

同時，各大製藥公司紛紛宣布對國內原料藥製造進行大規模投資。 2025 年 2 月，北美最大的製藥公司之一禮來公司宣布計劃投資 270 億美元在美國新建四家製造工廠。此次擴建旨在實現兩個目的：減少對海外原料藥來源的依賴，並減輕潛在藥品進口關稅的影響。這一策略轉變反映了製藥業的一個大趨勢，由於貿易不確定性和海外生產成本上升等因素，越來越多的公司將生產轉移回北美。作為這項舉措的一部分，禮來公司還在 2025 年 8 月確認將出售其新澤西工廠，並專注於根據以美國為中心的生產策略整合製造業務。預計此類大規模投資將對市場產生重大影響，提高本地生產能力並增強供應鏈彈性。

同時，監管變化正在塑造北美原料藥生產的格局。 2024 年 6 月，美國食品藥物管理局(FDA) 修訂了 21 CFR 第 211 部分，以加強藥品（包括原料藥）的現行良好生產規範 (CGMP)。這些修訂旨在改善整個產業的品質保證和生產流程，確保原料藥符合最高的安全性和有效性標準。這些監管更新鼓勵製藥商採用尖端技術和品管措施。此外，2024 年 1 月，FDA 發布了新的指導草案，澄清人用藥物 CGMP 指南 (ICH Q7) 也適用於原料藥的生產。此舉反映了 FDA 致力於加強監管和協調製藥業各個環節實踐的承諾。透過將法律規範擴大到原料藥，FDA 確保用於人類和動物健康的原料藥符契約樣嚴格的標準，從而提高藥品的整體安全性和有效性。

除了監管和投資主導的變化之外，技術進步對於塑造原料藥製造業也至關重要。一個關鍵趨勢是向連續製造轉變，這使得原料藥生產更有效率、可擴展且具有成本效益。 2023 年 5 月， 原料藥製造商 Cambrex 完成了其位於馬薩諸塞州的原料藥製造工廠的大規模擴建，提高了生產能力，以滿足對高品質、高效價原料藥日益成長的需求。此次擴建是該公司更廣泛策略的一部分，該策略旨在投資先進的製造技術，以提高生產效率並更快地響應不斷變化的市場需求。連續製造與自動化即時監控系統相結合，可幫助公司縮短生產前置作業時間、降低營運成本並最大限度地降低人為錯誤的風險。這些技術進步有望成為維持市場成長的關鍵因素，因為它們提高了靈活性和對醫藥需求變化的應對力。

這些發展標誌著北美正在齊心協力加強其國內原料藥）製造業。透過投資製造設施、法規更新和最尖端科技，該地區正致力於在全球市​​場動盪的背景下，增強自力更生和韌性。隨著學名藥和創新藥需求的不斷成長，北美原料藥市場預計將繼續發展，這些因素將有助於打造更穩健、更具前瞻性的醫藥供應鏈。該行業專注於增強製造能力、提高法規遵從性並採用先進技術，這將有助於北美在全球原料藥市場保持領先地位。

目錄

第1章調查方法與範圍

第2章執行摘要

3. 北美活性藥物成分市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

4. 北美活性藥物成分市場：按合成類型分類的業務分析

  • 2024年及2033年按合成類型分類的市場佔有率
  • 細分儀表板
  • 2021-2033 年按合成類型分類的市場規模、預測與趨勢分析
  • 生物技術
  • 合成

第5章北美活性藥物成分市場：製造商業務分析

  • 2024 年及 2033 年各廠商的市佔率
  • 製造商細分儀表板
  • 市場規模、預測和趨勢分析（按製造商，2021-2033 年）
  • 專屬式API
  • 商家 API

6. 北美活性藥物成分市場：按類型分類的業務分析

  • 2024 年及 2033 年各類型市場佔有率
  • 類型細分儀表板
  • 按類型分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 通用 API
  • 創新 API

7. 北美活性藥物成分市場：按應用分類的業務分析

  • 2024 年及 2033 年各應用領域的市場佔有率
  • 使用細分儀表板
  • 市場規模、預測與趨勢分析（按應用，2021-2033 年）
  • 心臟病學
  • 腫瘤學
  • 中樞神經系統和神經病學
  • 整形外科
  • 內分泌學
  • 呼吸系統醫療設備
  • 胃腸病學
  • 腎臟病學
  • 眼科
  • 其他

第8章北美活性藥物成分市場：各國估計與趨勢分析

  • 2024年及2033年各國活性藥物成分市佔率
  • 北美洲
    • 2021-2033年北美活性藥物成分市場
    • 美國
    • 加拿大
    • 墨西哥

第9章 競爭態勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Dr. Reddy's Laboratories Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Cipla Inc.
    • AbbVie Inc.
    • Aurobindo Pharma
    • Sandoz International GmbH（Novartis AG）
    • Viatris Inc.
    • Fresenius Kabi AG
    • STADA Arzneimittel AG
    • Lonza
    • Curia
    • Pfizer Inc
    • Bristol-Myers Squibb Company
    • Merck KGaA
    • Catalent, Inc.
Product Code: GVR-4-68040-221-1

North America Active Pharmaceutical Ingredients Market Summary

The North America active pharmaceutical ingredients market was estimated at USD 96.64 million in 2024 and is projected to reach USD 147.34 million by 2033, growing at a CAGR of 4.76% from 2025 to 2033. The increasing demand for generic drugs, advancements in biotechnology, a rising aging population, and favorable regulatory support drive this growth.

The presence of established pharmaceutical companies with strong manufacturing capabilities further supports the market's expansion. The North America API market is undergoing a significant transformation, driven by various dynamic factors, including regulatory initiatives, technological advancements, and strategic investments to bolster domestic manufacturing capabilities. One of the most prominent developments in this market is the U.S. government's efforts to ensure a more resilient pharmaceutical supply chain. In August 2025, President Donald Trump signed an executive order to establish the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) to stockpile critical drug components necessary for national health and security. This strategic initiative, supported by the U.S. Department of Health and Human Services, highlights the growing recognition of the vulnerabilities in the global API supply chain, especially following the disruptions caused by the COVID-19 pandemic. This move is intended to reduce dependence on foreign suppliers, ensuring that essential medicines are readily available during emergencies and disruptions.

Simultaneously, major pharmaceutical companies have announced significant investments in domestic API manufacturing. In February 2025, Eli Lilly, one of the largest pharmaceutical companies in North America, revealed plans to invest USD 27 billion to construct four new manufacturing facilities in the United States, with three of these facilities dedicated to API production. The purpose of this expansion is twofold: to reduce reliance on foreign sources of APIs and to mitigate the impact of potential pharmaceutical import tariffs. This strategic shift reflects broader trends in the pharmaceutical industry, where companies are increasingly bringing production back to North America, driven by factors such as trade uncertainties and rising costs of overseas manufacturing. As part of this initiative, Eli Lilly also confirmed in August 2025 that it would sell a New Jersey plant, focusing on consolidating its manufacturing operations to align with its U.S.-centric production strategy. Such large-scale investments are expected to impact the market significantly, increasing local production capacity and enhancing supply chain resilience.

Alongside these developments, regulatory changes are shaping the landscape of API manufacturing in North America. In June 2024, the U.S. Food and Drug Administration (FDA) amended 21 CFR Part 211, enhancing Current Good Manufacturing Practices (CGMP) for drug products, including APIs. These revisions aim to improve quality assurance and manufacturing processes across the industry, ensuring that APIs meet the highest safety and efficacy standards. Such regulatory updates push pharmaceutical manufacturers to adopt state-of-the-art technologies and quality control measures. Furthermore, in January 2024, the FDA released new draft guidance clarifying that the human drug CGMP guidelines (ICH Q7) now apply to manufacturing veterinary APIs. This move reflects the FDA's commitment to enhancing oversight and aligning practices across various pharmaceutical industry segments. By expanding regulatory oversight to include veterinary APIs, the FDA ensures that APIs used in human and animal health meet the same rigorous standards, thereby improving the overall safety and effectiveness of medications.

In addition to regulatory and investment-driven changes, technological advancements are pivotal in shaping the API manufacturing sector. A significant trend is the shift toward continuous manufacturing, which allows for more efficient, scalable, and cost-effective production of APIs. In May 2023, Cambrex, an API manufacturer, completed a large-scale expansion of its API production plant in Massachusetts, increasing its capacity to meet the growing demand for high-quality, high-potency APIs. This expansion is part of a broader strategy by companies to invest in advanced manufacturing technologies that enhance production efficiency and enable faster response times to changing market demands. Continuous manufacturing, which involves automated, real-time monitoring systems, helps companies reduce production lead times, lower operational costs, and minimize the risk of human error. These technological innovations are expected to be a key factor in sustaining market growth, as they offer greater flexibility and responsiveness to shifts in the demand for pharmaceutical products.

These developments indicate a concerted effort to strengthen North America's domestic API manufacturing sector. By leveraging investments in manufacturing facilities, regulatory updates, and cutting-edge technologies, the region is positioning itself to become more self-reliant and resilient in the face of global disruptions. With increasing demand for generic and innovative drugs, the North American API market is set to continue evolving, driven by these factors contributing to a more robust and future-proof pharmaceutical supply chain. The industry's focus on enhancing manufacturing capacity, improving regulatory compliance, and adopting advanced technologies will help ensure North America remains at the forefront of the global API market.

North America Active Pharmaceutical Ingredients Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the North America active pharmaceutical ingredients market report based on type of synthesis, type of manufacturer, type, application, and country:

  • Type of Synthesis Outlook (Revenue, USD Million, 2021 - 2033)
  • Biotech
    • Biotech APIs Market, By Type
    • Generic API
    • Innovative API
    • Biotech APIs Market, By Product
    • Monoclonal Antibodies
    • Hormones
    • Cytokines
    • Recombinant Proteins
    • Therapeutic Enzymes
    • Vaccines
    • Blood Factors
  • Synthetic
    • Synthetic APIs Market, By Type
    • Generic API
    • Innovative API
  • Type of Manufacturer Outlook (Revenue, USD Million, 2021 - 2033)
  • Captive APIs
  • Merchant APIs
    • Merchant APIs Market, By Type
    • Generic API
    • Innovative API
    • Merchant APIs Market, By Type of Synthesis
    • Biotech
    • Synthetic
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Generic API
  • Innovative API
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Cardiology
  • Oncology
  • CNS and Neurology
  • Orthopedic
  • Endocrinology
  • Pulmonology
  • Gastroenterology
  • Nephrology
  • Ophthalmology
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type of Synthesis
    • 1.2.2. Type of Manufacturer
    • 1.2.3. Type
    • 1.2.4. Application
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Source
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Source
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. North America Active Pharmaceutical Ingredients Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. North America Active Pharmaceutical Ingredients Market: Type of Synthesis Business Analysis

  • 4.1. Type of Synthesis Market Share, 2024 & 2033
  • 4.2. Type of Synthesis Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type of Synthesis, 2021 to 2033 (USD Million)
  • 4.4. Biotech
    • 4.4.1. Biotech Market, 2021 - 2033 (USD Million)
    • 4.4.2. Biotech APIs Market, By Type
      • 4.4.2.1. Biotech APIs Market, By Type Market, 2021 - 2033 (USD Million)
      • 4.4.2.2. Generic API
        • 4.4.2.2.1. Generic API Market, 2021 - 2033 (USD Million)
      • 4.4.2.3. Innovative API
        • 4.4.2.3.1. Innovative API Market, 2021 - 2033 (USD Million)
    • 4.4.3. Biotech APIs Market, By Product
      • 4.4.3.1. Biotech APIs Market, By Product Market, 2021 - 2033 (USD Million)
      • 4.4.3.2. Monoclonal Antibodies
        • 4.4.3.2.1. Monoclonal Antibodies Market, 2021 - 2033 (USD Million)
      • 4.4.3.3. Hormones
        • 4.4.3.3.1. Hormones Market, 2021 - 2033 (USD Million)
      • 4.4.3.4. Cytokines
        • 4.4.3.4.1. Cytokines Market, 2021 - 2033 (USD Million)
      • 4.4.3.5. Recombinant Proteins
        • 4.4.3.5.1. Recombinant Proteins Market, 2021 - 2033 (USD Million)
      • 4.4.3.6. Therapeutic Enzymes
        • 4.4.3.6.1. Therapeutic Enzymes Market, 2021 - 2033 (USD Million)
      • 4.4.3.7. Vaccines
        • 4.4.3.7.1. Vaccines Market, 2021 - 2033 (USD Million)
      • 4.4.3.8. Blood Factors
        • 4.4.3.8.1. Blood Factors Market, 2021 - 2033 (USD Million)
  • 4.5. Synthetic
    • 4.5.1. Synthetic Market, 2021 - 2033 (USD Million)
    • 4.5.2. Synthetic APIs Market, By Type
      • 4.5.2.1. Synthetic APIs Market, By Type Market, 2021 - 2033 (USD Million)
      • 4.5.2.2. Generic API
        • 4.5.2.2.1. Generic API Market, 2021 - 2033 (USD Million)
      • 4.5.2.3. Innovative API
        • 4.5.2.3.1. Innovative API Market, 2021 - 2033 (USD Million)

Chapter 5. North America Active Pharmaceutical Ingredients Market: Type of Manufacturer Business Analysis

  • 5.1. Type of Manufacturer Market Share, 2024 & 2033
  • 5.2. Type of Manufacturer Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Type of Manufacturer, 2021 to 2033 (USD Million)
  • 5.4. Captive APIs
    • 5.4.1. Captive APIs Market, 2021 - 2033 (USD Million)
  • 5.5. Merchant APIs
    • 5.5.1. Merchant APIs Market, 2021 - 2033 (USD Million)
  • 5.6. Merchant APIs Market, By Type
    • 5.6.1. Merchant APIs Market, By Type Market, 2021 - 2033 (USD Million)
    • 5.6.2. Generic API
      • 5.6.2.1. Generic API Market, 2021 - 2033 (USD Million)
    • 5.6.3. Innovative API
      • 5.6.3.1. Innovative API Market, 2021 - 2033 (USD Million)
  • 5.7. Merchant APIs Market, By Type of Synthesis
    • 5.7.1. Merchant APIs Market, By Type of Synthesis Market, 2021 - 2033 (USD Million)
    • 5.7.2. Biotech
      • 5.7.2.1. Biotech Market, 2021 - 2033 (USD Million)
    • 5.7.3. Synthetic
      • 5.7.3.1. Synthetic Market, 2021 - 2033 (USD Million)

Chapter 6. North America Active Pharmaceutical Ingredients Market: Type Business Analysis

  • 6.1. Type Market Share, 2024 & 2033
  • 6.2. Type Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 6.4. Generic API
    • 6.4.1. Generic API Market, 2021 - 2033 (USD Million)
  • 6.5. Innovative API
    • 6.5.1. Innovative API Market, 2021 - 2033 (USD Million)

Chapter 7. North America Active Pharmaceutical Ingredients Market: Application Business Analysis

  • 7.1. Application Market Share, 2024 & 2033
  • 7.2. Application Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 7.4. Cardiology
    • 7.4.1. Cardiology Market, 2021 - 2033 (USD Million)
  • 7.5. Oncology
    • 7.5.1. Oncology Market, 2021 - 2033 (USD Million)
  • 7.6. CNS and Neurology
    • 7.6.1. CNS and Neurology Market, 2021 - 2033 (USD Million)
  • 7.7. Orthopedic
    • 7.7.1. Orthopedic Market, 2021 - 2033 (USD Million)
  • 7.8. Endocrinology
    • 7.8.1. Endocrinology Market, 2021 - 2033 (USD Million)
  • 7.9. Pulmonology
    • 7.9.1. Pulmonology Market, 2021 - 2033 (USD Million)
  • 7.10. Gastroenterology
    • 7.10.1. Gastroenterology Market, 2021 - 2033 (USD Million)
  • 7.11. Nephrology
    • 7.11.1. Nephrology Market, 2021 - 2033 (USD Million)
  • 7.12. Ophthalmology
    • 7.12.1. Ophthalmology Market, 2021 - 2033 (USD Million)
  • 7.13. Others
    • 7.13.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. North America Active Pharmaceutical Ingredients Market: Country Estimates & Trend Analysis

  • 8.1. Active Pharmaceutical Ingredients Market Share By Country, 2024 & 2033
  • 8.2. North America
    • 8.2.1. North America Active pharmaceutical ingredients market, 2021 - 2033 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Target Disease Prevalence
      • 8.2.2.3. Competitive Scenario
      • 8.2.2.4. Regulatory Framework
      • 8.2.2.5. Reimbursement Scenario
      • 8.2.2.6. U.S. Active pharmaceutical ingredients market, 2021 - 2033 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Target Disease Prevalence
      • 8.2.3.3. Competitive Scenario
      • 8.2.3.4. Regulatory Framework
      • 8.2.3.5. Reimbursement Scenario
      • 8.2.3.6. Canada Active pharmaceutical ingredients market, 2021 - 2033 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Target Disease Prevalence
      • 8.2.4.3. Competitive Scenario
      • 8.2.4.4. Regulatory Framework
      • 8.2.4.5. Reimbursement Scenario
      • 8.2.4.6. Mexico Active pharmaceutical ingredients market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Dr. Reddy's Laboratories Ltd.
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Sun Pharmaceutical Industries Ltd.
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Teva Pharmaceutical Industries Ltd.
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Cipla Inc.
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. AbbVie Inc.
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Aurobindo Pharma
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Sandoz International GmbH (Novartis AG)
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Viatris Inc.
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Fresenius Kabi AG
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. STADA Arzneimittel AG
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives
    • 9.5.11. Lonza
      • 9.5.11.1. Overview
      • 9.5.11.2. Financial Performance
      • 9.5.11.3. Product Benchmarking
      • 9.5.11.4. Strategic Initiatives
    • 9.5.12. Curia
      • 9.5.12.1. Overview
      • 9.5.12.2. Financial Performance
      • 9.5.12.3. Product Benchmarking
      • 9.5.12.4. Strategic Initiatives
    • 9.5.13. Pfizer Inc
      • 9.5.13.1. Overview
      • 9.5.13.2. Financial Performance
      • 9.5.13.3. Product Benchmarking
      • 9.5.13.4. Strategic Initiatives
    • 9.5.14. Bristol-Myers Squibb Company
      • 9.5.14.1. Overview
      • 9.5.14.2. Financial Performance
      • 9.5.14.3. Product Benchmarking
      • 9.5.14.4. Strategic Initiatives
    • 9.5.15. Merck KGaA
      • 9.5.15.1. Overview
      • 9.5.15.2. Financial Performance
      • 9.5.15.3. Product Benchmarking
      • 9.5.15.4. Strategic Initiatives
    • 9.5.16. Catalent, Inc.
      • 9.5.16.1. Overview
      • 9.5.16.2. Financial Performance
      • 9.5.16.3. Product Benchmarking
      • 9.5.16.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 North America active pharmaceutical ingredients market, by Type of Synthesis, 2021 - 2033 (USD Million)
  • Table 4 North America active pharmaceutical ingredients market, by Type of Manufacturer, 2021 - 2033 (USD Million)
  • Table 5 North America active pharmaceutical ingredients market, by Type, 2021 - 2033 (USD Million)
  • Table 6 North America active pharmaceutical ingredients market, by Application, 2021 - 2033 (USD Million)
  • Table 7 US active pharmaceutical ingredients market, by Type of Synthesis, 2021 - 2033 (USD Million)
  • Table 8 US active pharmaceutical ingredients market, by Type of Manufacturer, 2021 - 2033 (USD Million)
  • Table 9 US active pharmaceutical ingredients market, by Type, 2021 - 2033 (USD Million)
  • Table 10 US active pharmaceutical ingredients market, by Application, 2021 - 2033 (USD Million)
  • Table 11 Canada active pharmaceutical ingredients market, by Type of Synthesis, 2021 - 2033 (USD Million)
  • Table 12 Canada active pharmaceutical ingredients market, by Type of Manufacturer, 2021 - 2033 (USD Million)
  • Table 13 Canada active pharmaceutical ingredients market, by Type, 2021 - 2033 (USD Million)
  • Table 14 Canada active pharmaceutical ingredients market, by Application, 2021 - 2033 (USD Million)
  • Table 15 Mexico active pharmaceutical ingredients market, by Type of Synthesis, 2021 - 2033 (USD Million)
  • Table 16 Mexico active pharmaceutical ingredients market, by Type of Manufacturer, 2021 - 2033 (USD Million)
  • Table 17 Mexico active pharmaceutical ingredients market, by Type, 2021 - 2033 (USD Million)
  • Table 18 Mexico active pharmaceutical ingredients market, by Application, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 North America active pharmaceutical ingredients market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 North America active pharmaceutical ingredients market dynamics
  • Fig. 11 North America active pharmaceutical ingredients market: Porter's five forces analysis
  • Fig. 12 North America active pharmaceutical ingredients market: PESTLE analysis
  • Fig. 13 Type of Synthesis market, 2021 - 2033 (USD Million)
  • Fig. 14 Biotech market, 2021 - 2033 (USD Million)
  • Fig. 15 Biotech APIs Market, By Type market, 2021 - 2033 (USD Million)
  • Fig. 16 Generic API market, 2021 - 2033 (USD Million)
  • Fig. 17 Innovative API market, 2021 - 2033 (USD Million)
  • Fig. 18 Biotech APIs Market, By Product market, 2021 - 2033 (USD Million)
  • Fig. 19 Monoclonal Antibodies market, 2021 - 2033 (USD Million)
  • Fig. 20 Hormones market, 2021 - 2033 (USD Million)
  • Fig. 21 Cytokines market, 2021 - 2033 (USD Million)
  • Fig. 22 Recombinant Proteins market, 2021 - 2033 (USD Million)
  • Fig. 23 Therapeutic Enzymes market, 2021 - 2033 (USD Million)
  • Fig. 24 Vaccines market, 2021 - 2033 (USD Million)
  • Fig. 25 Blood Factors market, 2021 - 2033 (USD Million)
  • Fig. 26 Synthetic market, 2021 - 2033 (USD Million)
  • Fig. 27 Synthetic APIs Market, By Type market, 2021 - 2033 (USD Million)
  • Fig. 28 Generic API market, 2021 - 2033 (USD Million)
  • Fig. 29 Innovative API market, 2021 - 2033 (USD Million)
  • Fig. 30 Type of Manufacturer market, 2021 - 2033 (USD Million)
  • Fig. 31 Captive APIs market, 2021 - 2033 (USD Million)
  • Fig. 32 Merchant APIs market, 2021 - 2033 (USD Million)
  • Fig. 33 Merchant APIs Market, By Type market, 2021 - 2033 (USD Million)
  • Fig. 34 Generic API market, 2021 - 2033 (USD Million)
  • Fig. 35 Innovative API market, 2021 - 2033 (USD Million)
  • Fig. 36 Merchant APIs Market, By Type of Synthesis market, 2021 - 2033 (USD Million)
  • Fig. 37 Biotech market, 2021 - 2033 (USD Million)
  • Fig. 38 Synthetic market, 2021 - 2033 (USD Million)
  • Fig. 39 Type market, 2021 - 2033 (USD Million)
  • Fig. 40 Generic API market, 2021 - 2033 (USD Million)
  • Fig. 41 Innovative API market, 2021 - 2033 (USD Million)
  • Fig. 42 Application market, 2021 - 2033 (USD Million)
  • Fig. 43 Cardiovascular Diseases market, 2021 - 2033 (USD Million)
  • Fig. 44 Oncology market, 2021 - 2033 (USD Million)
  • Fig. 45 CNS and Neurology market, 2021 - 2033 (USD Million)
  • Fig. 46 Orthopedic market, 2021 - 2033 (USD Million)
  • Fig. 47 Endocrinology market, 2021 - 2033 (USD Million)
  • Fig. 48 Pulmonology market, 2021 - 2033 (USD Million)
  • Fig. 49 Gastroenterology market, 2021 - 2033 (USD Million)
  • Fig. 50 Nephrology market, 2021 - 2033 (USD Million)
  • Fig. 51 Ophthalmology market, 2021 - 2033 (USD Million)
  • Fig. 52 Others market, 2021 - 2033 (USD Million)
  • Fig. 53 North America active pharmaceutical ingredients market revenue, by country
  • Fig. 54 Country marketplace: Key takeaways
  • Fig. 55 U.S. country dynamics
  • Fig. 56 U.S. Active pharmaceutical ingredients market, 2021 - 2033 (USD Million)
  • Fig. 57 Germany country dynamics
  • Fig. 58 Canada Active pharmaceutical ingredients market, 2021 - 2033 (USD Million)
  • Fig. 59 Mexico country dynamics
  • Fig. 60 Mexico Active pharmaceutical ingredients market, 2021 - 2033 (USD Million)